New benchmarks on protocol design practices and their impact on clinical trial performance and efficiency will be discussed at the MCC Study Quality Trailblazer Community of Practice meeting on March 10, 2021.
Ken Getz, Michael Wilkinson and Zak Smith from Tufts Center for the Study of Drug Development will present the key findings and implications from their 2020 study. The results from this working group study show that scientific and operating complexity is continuing to rise with notably variation by disease condition. The study presents new insights into the volume and diversity of data collected per clinical trial and provides new benchmarks and insights into adaptive and master protocol designs. Join us to hear the findings first-hand and ask your questions.
Additional information about this MCC member group can be found by visiting the MCC Study Quality Trailblazer community of practice page. MCC Members can log onto the MCC member portal to register for the session.
Not a member? Contact Terry Holland, MCC Membership Director, to discuss membership options.